Αρχική World News Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with... World News Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma Από Ogkologos - 21 Σεπτεμβρίου, 2026 222 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the final 5-year analysis of overall survival in the IMCgp100-202 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR EMA Recommends Extension of Indications for Tafasitamab 4 Δεκεμβρίου, 2025 As Use of Genomic Data Expands in Cancer Care, Patients Share... 3 Δεκεμβρίου, 2019 Be a Holiday Helper! 14 Δεκεμβρίου, 2022 Why it’s difficult to estimate the number of extra cancer deaths... 21 Ιουλίου, 2020 Φόρτωση περισσοτέρων HOT NEWS A Meaningful Benefit of the Quadruplet-Based Isatuximab Plus VRd Regimen in... How Therapy Helped Me Cope During Cancer: A Survivor’s Perspective EMA Recommends Extension of Indications for Selumetinib Some Children with Wilms Tumor Can Receive Less Therapy, Study Suggests